

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 19<sup>th</sup> October, 2020

To,  
Bombay Stock Exchange Limited  
Department of Corporate Services  
25<sup>th</sup> Floor, P. J. Towers, Dalal Street,  
Mumbai-400001

Script Id : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter and Half Year ended 30<sup>th</sup> September, 2020 as under -


1.	Regulation 33	Un-audited Quarterly and Half Yearly Financial Results along with Statement of Assets And Liabilities for the Quarter and Half Year ended 30/09/2020 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 19/10/2020

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

  
SHREENIWAS SOMANI  
DIRECTOR  
(DIN - 00077939)



Place: Mumbai

Encl: as above



**VMD & CO.**  
CHARTERED ACCOUNTANTS

AVMS PREMISES,  
4<sup>TH</sup> FLOOR,  
SHREENIWAS HOUSE,  
27, H.S. MARG, FORT,  
MUMBAI- 400 001  
TEL. 2207 7707  
FAX 2207 1070  
info@vmd.co.in

### **LIMITED REVIEW REPORT**

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30<sup>th</sup> September 2020**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Dated: October 3, 2020**  
**Place: Mumbai**  
**UDIN: 20114222AAAAFD4224**

**For M/s VMD & Co.**  
**Chartered Accountants**  
**FRN: 125002W**

**CA Amit Ganpule**  
**Partner**  
**MRN: 114222**

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301  
 • Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001  
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
 Website: www.thechemopharmalaboratoriesLtd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2020

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2020	30th June 2020	30th Sept 2019	30th Sept 2020	30th Sept 2019	31st March 2020
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations						-
II	Other Income	1,428	1,563	2,779	2,991	5,610	9,967
III	<b>Total Revenue (I + II)</b>	<b>1,428</b>	<b>1,563</b>	<b>2,779</b>	<b>2,991</b>	<b>5,610</b>	<b>9,967</b>
IV	<b>Expenses</b>						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	216	245	430	461	835	1,813
	(5) Depreciation and Amortisation Expenses	-	-	-	-	-	231
	(6) Administrative and Other Expenses	200	431	564	631	1,487	2,982
	i) Professional Charges	-	-	-	-	-	-
	ii) Annual Listing Fees	-	-	-	-	-	-
	iii) Travelling Expenses	-	-	-	-	-	-
	iv) Postal Charges	-	-	-	-	-	-
	(7) Finance Costs	-	-	-	-	-	-
	<b>Total Expenses</b>	<b>416</b>	<b>676</b>	<b>994</b>	<b>1,092</b>	<b>2,322</b>	<b>5,026</b>
V	<b>Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)</b>	<b>1,012</b>	<b>887</b>	<b>1,785</b>	<b>1,899</b>	<b>3,288</b>	<b>4,941</b>
VI	Exceptional Items	-	-	-	-	-	-
VII	<b>Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)</b>	<b>1,012</b>	<b>887</b>	<b>1,785</b>	<b>1,899</b>	<b>3,288</b>	<b>4,941</b>
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	<b>Profit/(Loss) before Tax (VII-VIII)</b>	<b>1,012</b>	<b>887</b>	<b>1,785</b>	<b>1,899</b>	<b>3,288</b>	<b>4,941</b>
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	760
	(2) Tax Adjustment Previous Year	-	56	-	56	-	30
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	<b>1,012</b>	<b>831</b>	<b>1,785</b>	<b>1,843</b>	<b>3,288</b>	<b>4,151</b>
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	<b>Profit/(Loss) for the period (XI - XIV)</b>	<b>1,012</b>	<b>831</b>	<b>1,785</b>	<b>1,843</b>	<b>3,288</b>	<b>4,151</b>
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	<b>1,012</b>	<b>831</b>	<b>1,785</b>	<b>1,843</b>	<b>3,288</b>	<b>4,151</b>
XVIII	<b>Earnings per Share :</b>						
	(1) Basic	<b>0.67</b>	<b>0.55</b>	<b>1.19</b>	<b>1.23</b>	<b>2.19</b>	<b>2.77</b>
	(2) Diluted						

**Notes :**

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2020 have been reviewed by the Audit Committee in their Meeting held on 19.10.2020 and approved by the Board of Directors of its Meeting held on 19.10.2020. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai  
Date : 19.10.2020



For Chemo Pharma Laboratories Limited

Shreenivas Somani  
Director

(DIN - 00077939)

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301  
 • Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001  
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K  
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2020

(Rs. In Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
<b>Reconciliation of Profit After Tax as reported earlier:</b>						
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>1,012.00</b>	<b>831.00</b>	<b>1,785.00</b>	<b>1,843.00</b>	<b>3,288.00</b>	<b>4,151.00</b>
<b>Benefit / (Charge):</b>	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
<b>Net Profit / (Loss) for the Period (as per AS)</b>	<b>1,012.00</b>	<b>831.00</b>	<b>1,785.00</b>	<b>1,843.00</b>	<b>3,288.00</b>	<b>4,151.00</b>



For Chemo Pharma Laboratories Limited

Shreeniwas Somani  
Director

(DIN - 00077939)

Mumbai,  
19.10.2020

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2020

(Rupees in thousands)

PARTICULARS	Half Year Ended 30.09.2020 Unaudited	Year Ended 31.03.2020 Audited
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Net Profit before tax and extraordinary items	1,899	4,941
<b>Adjustment for</b>		
Depreciation	-	231
Liabilities written back	-	-
Dividend received	-	(5)
Interest received	(2,991)	(9,962)
<b>Operating profit before working capital changes</b>	<b>(1,092)</b>	<b>(4,795)</b>
<b>Adjustment for</b>		
Increase (Decrease) in other Current Liabilities	(224)	1,295
Decrease (increase) in Current Assets	(2,423)	54,711
Increase in Fixed Assets	(14)	(948)
Increase in Loan Given	-	(1,150)
<b>Cash Generated From Operation</b>	<b>(2,661)</b>	<b>53,908</b>
Taxes Paid	(56)	(790)
<b>A. Cash Flow From Operating Activities</b>	<b>(3,809)</b>	<b>48,323</b>
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Dividend received	-	5
Interest received	2,991	9,962
Decrease in Investment	-	132
<b>Cash Flow From Investing Activities</b>	<b>2,991</b>	<b>10,099</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Interest Paid	-	-
Long Term / Short Term Borrowings	-	-
Short Term Investment / Loan	-	-
<b>Cash Flow From Financing Activities</b>	<b>-</b>	<b>-</b>
Net increase/(decrease) in cash and cash Equivalents	(818)	58,422
Opening balance of Cash and Cash Equivalents	88,084	29,662
<b>Closing Balance Of Cash and Cash Equivalents</b>	<b>87,266</b>	<b>88,084</b>



Place : Mumbai  
Date : 19.10.2020

For Chemo Pharma Laboratories Limited

  
Shreeniwas Somani  
Director

(DIN - 00077939)

# CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3<sup>rd</sup> Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

## STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2020

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 30.09.2020 Unaudited	As at 31.03.2020 Audited
1	<b>ASSETS</b>		
1	<b>Non-Current Assets</b>		
	(A) Property, Plant & Equipment	761	747
	(B) Financial Assets		
	(i) Investment	237	237
	(ii) Long Term Loans	19,568	19,568
	<b>Total Non-Current Assets</b>	<b>20,566</b>	<b>20,552</b>
2	<b>Current Assets</b>		
	(i) Cash & Cash Equivalents	87,266	88,084
	(ii) Loans	3,444	1,021
	<b>Total Current Assets</b>	<b>90,710</b>	<b>89,105</b>
	<b>TOTAL ASSETS</b>	<b>111,276</b>	<b>109,657</b>
2	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	94,290	92,447
	<b>Total Equity</b>	<b>109,290</b>	<b>107,447</b>
2	<b>Liabilities</b>		
1	<b>Non-Current Liabilities</b>	-	-
2	<b>Current Liabilities</b>		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,986	1,450
	(iii) Provisions	-	760
	<b>Total Current Liabilities</b>	<b>1,986</b>	<b>2,210</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>111,276</b>	<b>109,657</b>

By Order of the Board



For Chemo Pharma Laboratories Limited

Shreeniwas Somani  
Director

(DIN - 00077939)

Place : Mumbai

Date : 19.10.2020